HIV PrEP for Men: Pills, Injections, Side Effects, and Who Should Consider It

HIV PrEP is a prevention medicine for people who do not have HIV but want strong protection before possible exposure. For men, that usually means thinking about sexual risk in a practical way: partners, condom use, recent STIs, injection drug use, and whether a partner with HIV has an undetectable viral load. PrEP is not only for one “type” of person. It is for anyone whose real life makes HIV prevention worth planning ahead.

Today, PrEP is no longer limited to one daily pill. Men may have options that include daily oral tablets, cabotegravir injections every 2 months, and lenacapavir injections every 6 months, depending on country, clinic access, medical history, and insurance or cost. Each choice works differently, and the best one is often the one a person can use correctly and consistently.

Table of Contents

• What PrEP Does, and What It Does Not Do
• Who Should Consider HIV PrEP?
• PrEP Options for Men: Pills and Long-Acting Injections
• How to Choose the Right PrEP Method
• Testing, Follow-Up, and What Happens Before Starting
• Side Effects, Safety Checks, and Drug Interactions
• Missed Doses, Stopping PrEP, and Switching Methods
• Sex, STIs, Condoms, and Your Next Step

What PrEP Does, and What It Does Not Do

PrEP stands for pre-exposure prophylaxis. In plain language, it means taking HIV medicine before exposure so the virus has a much harder time establishing infection. When used as prescribed, PrEP is extremely effective at preventing HIV from sex.

PrEP is different from PEP. PrEP is planned prevention before possible exposure. PEP, or post-exposure prophylaxis, is an emergency medication course started after a possible exposure, usually as soon as possible and within 72 hours. If you had a recent condom break, needle-sharing exposure, or unprotected sex with a partner who may have HIV and you are not already protected by PrEP, that is a PEP question, not a “start PrEP later” question.

PrEP also does not treat HIV by itself. This point matters because starting PrEP while already having early HIV can lead to delayed diagnosis and drug resistance. A clinician should confirm that you do not have HIV before starting, especially if you recently had fever, swollen glands, sore throat, rash, night sweats, body aches, or a flu-like illness after a possible exposure. Men who are unsure about symptoms should review early HIV symptoms and testing windows and arrange proper testing rather than guessing.

PrEP does not prevent chlamydia, gonorrhea, syphilis, herpes, HPV, hepatitis C, or mpox. It is one part of sexual health, not a replacement for condoms, vaccines, STI screening, partner communication, or treatment when needed.

The simplest way to think about it is this: PrEP is excellent HIV protection, but it is not full sexual health protection. A strong plan often combines PrEP with STI testing, condoms when they fit the situation, hepatitis B vaccination if needed, HPV vaccination when appropriate, and honest follow-up with a clinician.

Who Should Consider HIV PrEP?

A man should consider PrEP if his chance of HIV exposure is more than occasional or theoretical. You do not need to prove that you are “high risk” to ask about it. You also do not need to wait until something goes wrong. PrEP is most useful when it is started before anxiety, a condom accident, or a partner’s unknown status becomes an emergency.

PrEP is worth discussing if any of these apply:

• You have anal or vaginal sex with partners whose HIV status is unknown.
• You have condomless sex, even if not every time.
• You have had gonorrhea, chlamydia, syphilis, or another STI recently.
• You have multiple partners or a partner who has other partners.
• You have a partner with HIV who is not consistently undetectable or whose viral load is unknown.
• You use injection drugs and share needles, syringes, cookers, or other equipment.
• You exchange sex for money, housing, drugs, or other needs.
• You often feel anxious after sex because you are unsure whether you were protected.

For gay, bisexual, and other men who have sex with men, PrEP is often especially relevant because receptive anal sex carries a higher HIV transmission risk than many other sexual exposures when no prevention is used. Insertive anal sex also carries risk, and the risk increases when there are STIs, bleeding, condom breaks, or partners with unknown status.

Straight men may also benefit from PrEP. A man with a female partner who has HIV, a partner who injects drugs, a partner from a community with higher HIV prevalence, or partners whose status is unknown should not dismiss PrEP because he is heterosexual. The decision should follow actual exposure, not identity.

Transgender men and gender-diverse people should choose PrEP based on the type of sex they have, anatomy involved, pregnancy possibility if relevant, kidney health, medication interactions, and personal preference. Not every PrEP option has the same evidence for every exposure route, so a clinician should match the method to the person rather than make assumptions.

One common mistake is waiting for a partner to “look risky.” HIV status is not visible. Fitness, income, masculinity, cleanliness, age, and confidence say nothing reliable about HIV. Better decision points are recent test results, viral load if a partner has HIV, condom use, STI history, and whether you can use your prevention plan consistently.

PrEP Options for Men: Pills and Long-Acting Injections

Men now have several PrEP options in places where all approved medications are available. Access varies by country, clinic, insurance plan, and local guidelines, but the main choices are daily pills and long-acting injections.

Option	How it is used	Best fit	Main drawbacks
F/TDF pill	One tablet daily; some adult gay and bisexual men use off-label event-driven dosing under clinician guidance	Men who want a proven, often lower-cost pill option	Requires kidney checks; small bone and kidney effects matter for some users
F/TAF pill	One tablet daily	Some men who want a daily pill with less kidney and bone impact than F/TDF	Requires lipid and weight monitoring; not studied for receptive vaginal sex
Cabotegravir injection	Clinic injection, then another after 1 month, then every 2 months	Men who struggle with daily pills or prefer clinic-based protection	Requires on-time visits; injection soreness is common
Lenacapavir injection	Oral loading doses plus subcutaneous injections, then every 6 months	Men who want the longest-acting PrEP option where available	Injection nodules may last months; access and cost may limit use

Daily F/TDF

F/TDF means emtricitabine plus tenofovir disoproxil fumarate. It is the older, widely used PrEP pill and is available as a generic in many places. It has strong evidence for preventing HIV from sex when taken correctly and is also used for people with injection drug exposure.

Daily use is straightforward: one pill every day. The challenge is consistency. Missing a single pill is not usually a disaster, but repeated missed doses lower protection. Men who travel often, hide medications, work irregular shifts, or dislike daily reminders may find a daily tablet harder than expected.

Some adult gay and bisexual men use “2-1-1” or event-driven F/TDF dosing: two pills before sex, one pill 24 hours later, and one pill 48 hours later. This approach is used in some guidelines and clinical settings, but it is not FDA-approved and is not recommended by the CDC as a standard approach. It is not appropriate for everyone, especially people with active hepatitis B, people who have trouble following complex dosing, and people whose sex is not predictable.

Daily F/TAF

F/TAF means emtricitabine plus tenofovir alafenamide. It is also a daily pill. Compared with F/TDF, it tends to have less impact on kidney markers and bone mineral density, which matters for some men with kidney concerns, low bone density, or other risk factors.

The tradeoff is that F/TAF is not simply “better.” It may affect cholesterol, triglycerides, and weight in some users, so baseline and follow-up metabolic checks matter. It also has not been studied for HIV prevention in people exposed through receptive vaginal sex, so it is not the right universal substitute for F/TDF.

For many men, the choice between F/TDF and F/TAF comes down to kidney function, bone health, cost, insurance coverage, metabolic health, and whether the evidence matches their type of exposure.

Injectable cabotegravir and lenacapavir

Cabotegravir is a long-acting injection given into the muscle. After the first injection, a second dose is given 1 month later, then injections continue every 2 months. It is a good option for men who dislike daily pills, forget pills, have privacy concerns at home, or have kidney disease that makes oral tenofovir-based PrEP a poor fit.

Lenacapavir is longer acting. It is given as subcutaneous injections with oral loading doses at the start, then maintenance injections every 6 months. It creates a medication depot under the skin, which explains why bumps or nodules at the injection site may last much longer than typical shot soreness.

Men comparing the two injectable choices should look beyond “every 2 months” versus “every 6 months.” They should ask about local availability, insurance approval, what happens if a visit is missed, how HIV testing is handled, possible drug interactions, and how the clinic manages the medication “tail” after stopping. A deeper guide to long-acting injectable PrEP can help men compare timing and practical safety issues before choosing.

How to Choose the Right PrEP Method

The best PrEP method is the one that fits your risk pattern, health profile, and daily life. A medication that looks ideal on paper will not help much if you cannot take it, attend visits, pay for it, or keep it private.

Start with your biggest barrier. If remembering pills is the problem, injections deserve attention. If clinic visits are difficult, daily pills may be simpler. If kidney function is reduced, injectable PrEP or F/TAF may be more appropriate than F/TDF. If cholesterol or weight is already a concern, F/TDF or an injection may fit better than F/TAF, depending on the full medical picture.

Privacy also matters. Some men prefer pills because they control them at home. Others hate having a bottle that a partner, roommate, parent, or coworker might find. Injections remove the daily pill bottle but require clinic appointments, insurance paperwork, and sometimes visible or feelable injection-site changes.

Cost is another real decision point. Generic F/TDF is often the most affordable option. F/TAF and injectable PrEP are usually more expensive, though assistance programs, public clinics, or insurance coverage may change the out-of-pocket cost. Do not assume the “newest” option is the most realistic option until the clinic checks coverage.

Sex pattern matters too. A man with frequent or unpredictable sex often does better with daily or long-acting protection already in place. A man with rare, planned sex might ask whether event-driven F/TDF is appropriate, but only with a clinician who understands the dosing and limitations.

Use this practical filter:

• Choose a daily pill if you want control, easy stopping, lower cost, and no injection visits.
• Consider F/TDF if you have normal kidney function and want the most established oral option.
• Consider F/TAF if kidney or bone concerns make F/TDF less attractive, and your exposure type matches the evidence.
• Consider cabotegravir if daily pills are hard and you can attend visits every 2 months.
• Consider lenacapavir if you want the longest dosing interval and can manage its clinic schedule, loading doses, and injection-site tradeoffs.

A good PrEP visit should feel like shared decision-making, not a lecture. The clinician should ask how you actually live: how often you have sex, whether partners are predictable, whether you use condoms, whether you have had STIs, whether you inject drugs, what medicines you take, whether you have kidney or liver issues, and whether you can attend follow-up visits.

Testing, Follow-Up, and What Happens Before Starting

Starting PrEP is not complicated, but it should not be casual. The key safety step is confirming that you do not already have HIV. This usually involves a lab-based HIV antigen/antibody test, and in some situations an HIV RNA test, especially when recent infection is possible or when starting or continuing injectable PrEP.

Before starting oral PrEP, clinicians commonly check kidney function with a blood creatinine test and calculate estimated creatinine clearance. For tenofovir-based pills, kidney function matters because the medication is processed through the kidneys. People starting oral PrEP should also be screened for hepatitis B, because stopping tenofovir-based medication in someone with active hepatitis B can cause a flare.

Baseline STI testing is also important. That often means urine, throat, rectal, and blood testing depending on the sex you have. A urine-only STI test misses throat and rectal infections. Men who have oral or receptive anal sex should ask directly which sites are being tested. A practical guide to STI testing timing and test types is useful if you are unsure what to request.

Follow-up depends on the method:

• Daily oral PrEP usually requires HIV testing at least every 3 months, with refills limited until the next HIV test.
• Kidney monitoring is repeated periodically for oral PrEP, more often for men over 50 or those with lower baseline kidney function, diabetes, hypertension, or kidney-risk medicines.
• F/TAF users should also have cholesterol, triglycerides, and weight monitored.
• Cabotegravir users return for scheduled injections and HIV testing, including HIV RNA testing in many protocols.
• Lenacapavir users need HIV testing before injections and careful follow-up around the 6-month dosing schedule.

The first PrEP visit is also a good time to update vaccines. Hepatitis B vaccination is especially relevant if you are not immune. HPV vaccination may matter for younger men and some adults through age 45 after shared decision-making. Hepatitis A vaccination is also recommended for some men based on sexual practices, travel, liver disease, or local guidance.

Do not hide symptoms because you want to start quickly. If you recently had a high-risk exposure and now have a fever, rash, sore throat, swollen lymph nodes, diarrhea, night sweats, or severe fatigue, tell the clinician before starting. Early HIV can be missed if the wrong test is used at the wrong time.

Side Effects, Safety Checks, and Drug Interactions

Most men tolerate PrEP well. Side effects are usually mild, especially compared with the benefit of preventing HIV. Still, each option has different safety points.

Daily F/TDF can cause nausea, loose stools, headache, or stomach discomfort during the first few weeks. These often improve as the body adjusts. The bigger monitoring issue is kidney function. Small kidney marker changes are usually reversible after stopping, but men with kidney disease, diabetes, high blood pressure, heavy NSAID use, or other kidney-risk medicines need closer attention. F/TDF can also slightly reduce bone mineral density in some users, which matters more for adolescents, men with osteoporosis risk, long-term steroid use, eating disorders, or prior fragility fractures.

Daily F/TAF tends to be gentler on kidney and bone markers, but it has its own tradeoffs. Some users have increases in cholesterol, triglycerides, or weight. That does not mean every man gains weight or develops lipid problems, but it does mean labs should be checked rather than ignored.

Cabotegravir’s most common issue is injection-site reaction. Pain, tenderness, swelling, warmth, or a lump can happen after the shot. These reactions are usually mild or moderate and fade, but some men find them annoying. A smaller number of users experience feverish feelings, fatigue, headache, muscle aches, or nausea. A more serious concern is delayed HIV detection if infection occurs while drug levels are present, which is why proper HIV testing matters.

Lenacapavir commonly causes injection-site reactions too, especially nodules, firmness, pain, or induration under the skin. Unlike ordinary shot soreness, nodules can last for months and sometimes longer. Men who are bothered by visible or feelable lumps should discuss injection location, technique, and expectations before choosing this method.

Drug interactions are another reason not to order PrEP casually without a medical review. Some antiseizure medicines, tuberculosis medicines, HIV medicines, hepatitis medicines, and other drugs may interfere with long-acting options or require a different plan. High-dose or frequent NSAID use can add kidney stress for men taking tenofovir-based pills. Supplements are worth mentioning too, especially if they affect the liver, kidneys, or other prescriptions.

PrEP is not a good place for partial honesty. Tell the clinician about all prescription medicines, over-the-counter pain relievers, bodybuilding drugs, supplements, kidney problems, liver disease, hepatitis B, past HIV tests, and recent PEP or PrEP use. That information helps choose the safest method; it is not there to judge you.

Missed Doses, Stopping PrEP, and Switching Methods

Missed doses happen. The right response depends on which PrEP method you use and how much HIV exposure is likely during the gap.

For daily oral PrEP, an occasional missed pill is usually handled by taking the next dose when remembered and continuing the schedule. Do not double up repeatedly unless your clinician gives that instruction. The bigger issue is a pattern: missed pills several times a week, long gaps, or stopping during a period when sex continues. In that situation, protection drops and you should talk with a clinician about whether to restart, test, use condoms, switch methods, or consider PEP after a recent exposure.

For event-driven F/TDF, timing is the whole method. It only works when the before-and-after doses are taken correctly. If sex happens sooner than planned, if the first two-pill dose was missed, or if after-sex doses were forgotten, ask a clinician or sexual health clinic what to do. Do not assume event-driven dosing protects every exposure.

For cabotegravir, late injections matter. Long-acting medication levels decline slowly, but falling drug levels can create a period where protection is weaker and, if HIV is acquired, resistance becomes a concern. Clinics usually have protocols for missed visits, restart testing, and temporary oral PrEP coverage.

For lenacapavir, the long tail is even more important. After stopping, medication levels decline over a long period, but protection does not last indefinitely. A man who stops lenacapavir and still has HIV exposure needs another prevention plan, not a vague assumption that the last injection is “still in there.”

Switching methods is common and reasonable. Men switch because of cost, side effects, new relationships, travel, kidney labs, privacy, injection fatigue, or a change in sexual activity. The safest switch is planned. Ideally, do not leave a gap between the old method wearing off and the new method becoming protective.

Stopping PrEP is reasonable when HIV exposure has truly changed. Examples include a mutually monogamous relationship where both partners have recent negative tests, a partner with HIV who is consistently undetectable, no ongoing sexual exposure, or stopping injection drug use with no equipment sharing. Even then, it is smart to discuss timing with a clinician before stopping, especially for hepatitis B, recent exposures, or injectable PrEP tails.

Sex, STIs, Condoms, and Your Next Step

PrEP lowers HIV anxiety for many men, but it should not make STI care disappear. In fact, regular PrEP visits are a good chance to catch silent infections early. Chlamydia, gonorrhea, and syphilis often cause no symptoms, especially in the throat or rectum. Untreated infections can spread to partners and sometimes cause pain, discharge, testicular problems, pelvic discomfort, or broader health issues.

Condoms still matter. They reduce HIV risk, add STI protection, and help prevent pregnancy in partners who can become pregnant. They are also useful during PrEP gaps, after missed doses, while waiting for testing, and with partners whose STI status is unknown. Many condom failures come from fit, friction, expired condoms, oil-based products, or late application; reviewing condom fit and breakage mistakes can prevent problems that are easy to fix.

Some men on PrEP should also ask about DoxyPEP, which means doxycycline post-exposure prophylaxis for certain bacterial STIs after sex. It is not for everyone, and it does not prevent HIV, viral infections, or all bacterial STIs. It is most relevant for selected people with recent bacterial STIs or ongoing higher exposure. A separate guide to DoxyPEP for STI prevention can help you understand who benefits and what risks to discuss.

Oral and rectal exposures deserve attention too. A throat infection can be silent. A rectal infection can cause discharge, bleeding, pain, urgency, or no symptoms at all. Men who have oral or anal sex should not rely on urine testing alone. Testing should match the body sites used during sex; otherwise, infections are missed. For a closer look at throat, genital, and rectal risks, see oral sex and STI risks in men.

Your next step is simple: if HIV exposure is possible in your life, book a PrEP conversation before the next stressful moment. Ask which options are available, what labs you need, how soon protection starts for your type of sex, what the method costs, what happens if you miss doses, and how often you need STI testing.

A good PrEP plan should leave you with clear answers:

• Which PrEP method am I using?
• When am I protected for the kind of sex I have?
• What tests do I need before starting and during follow-up?
• What side effects should I expect, and which ones need medical advice?
• What should I do after a missed pill, late injection, condom break, or new exposure?
• How will I keep up with STI screening, vaccines, and condoms when needed?

PrEP works best when it fits real life. The right choice is not about looking responsible to someone else. It is about having reliable HIV protection that you understand, can access, and can keep using when it matters.

References

• Clinical Guidance for PrEP 2026 (Guideline)
• Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025 2025 (Guideline)
• Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis 2025 (Guideline)
• Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons 2025 (RCT)
• Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women 2021 (RCT)

Disclaimer

This article is for education and does not replace care from a qualified clinician. HIV PrEP requires proper HIV testing before starting, follow-up testing while using it, and individualized review of kidney function, hepatitis B status, medication interactions, side effects, and sexual exposure. If you had a possible HIV exposure within the last 72 hours, seek urgent medical advice about PEP rather than waiting for a routine PrEP visit.